Theravance Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024PRNewsWire • 02/14/24
Down -11.17% in 4 Weeks, Here's Why Theravance Bio (TBPH) Looks Ripe for a TurnaroundZacks Investment Research • 01/12/24
Theravance Biopharma's stock slides 21% after Phase 4 trial of COPD treatment fails to meet main goalMarket Watch • 01/05/24
Theravance Biopharma Announces Results from the Phase 4 YUPELRI® PIFR-2 Study in Patients with Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD)PRNewsWire • 01/05/24
Theravance Biopharma, Inc. Announces Appointment of Jeremy Grant to Board of DirectorsPRNewsWire • 12/21/23
Theravance Biopharma to Conduct Investor Meetings During the J.P. Morgan 42nd Annual Healthcare ConferencePRNewsWire • 12/18/23
Theravance Bio (TBPH) Up 2.5% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 12/07/23
Theravance Biopharma to Present New Ampreloxetine Data at the 34th International Symposium on The Autonomic Nervous SystemPRNewsWire • 11/16/23
Theravance Biopharma to Participate in the 6th Annual Evercore ISI HealthCONx ConferencePRNewsWire • 11/15/23
Viatris and Theravance Biopharma Announce Positive Top-Line Results from YUPELRI® (revefenacin) Phase III Trial in China for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)PRNewsWire • 11/13/23
Theravance Biopharma, Inc. Reports Third Quarter 2023 Financial Results and Provides Business UpdatePRNewsWire • 11/07/23
Theravance Biopharma to Report Third Quarter 2023 Financial Results on November 7, 2023PRNewsWire • 10/19/23
Theravance Biopharma: YUPELRI Numbers Don't Substantiate 9x Forward Sales, Rate HoldSeeking Alpha • 09/08/23
Theravance Biopharma to Present New Ampreloxetine Data at the 2023 International Congress of Parkinson's Disease and Movement DisordersPRNewsWire • 08/28/23
Theravance Biopharma, Inc. Reports Second Quarter 2023 Financial Results and Provides Business UpdatePRNewsWire • 08/07/23
Theravance Biopharma to Report Second Quarter 2023 Financial Results on August 7, 2023PRNewsWire • 07/24/23
Why Is Theravance Bio (TBPH) Down 3.8% Since Last Earnings Report?Zacks Investment Research • 06/07/23
Theravance Biopharma, Inc. Announces Orphan Drug Designation Granted to Ampreloxetine for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Patients with Multiple System AtrophyPRNewsWire • 05/09/23